Active Ingredient History
Fesoterodine (trade name Toviaz) is a prodrug of 5-hydroxymethyl tolterodine, which is also the active metabolite of tolterodine. Fesoterodine and its active metabolites are nonsubtype selective, competitive antagonists of human muscarinic receptors, but 5-hydroxymethyl tolterodine has greater potency than the parent compound. A prodrug approach was necessary for systemic bioavailability of 5-hydroxymethyl tolterodine after oral administration. Fesoterodine was originated by Schwarz Pharma (later a subsidiary of UCB) and is being developed by Pfizer for the treatment of overactive bladder and urinary urge incontinence. The agent is launched in several countries for the treatment of overactive bladder, including the US, Japan, Canada, Europe and Asia. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Autonomic Dysreflexia (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Intraductal, Noninfiltrating (Phase 2)
Cognitive Dysfunction (Phase 2)
Food (Phase 1)
Healthy Volunteers (Phase 1)
Nocturia (Phase 2/Phase 3)
Parkinson Disease (Phase 4)
Prostatic Neoplasms (Phase 4)
Therapeutic Equivalency (Phase 1)
Urinary Bladder (Phase 2)
Urinary Bladder Neck Obstruction (Phase 4)
Urinary Bladder, Neurogenic (Phase 3)
Urinary Incontinence, Stress (Phase 2)
Urinary Incontinence, Urge (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue